Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Blood (2019) 134 (Supplement_1): 2943.

https://doi.org/10.1182/blood-2019-124865

Published: 2019

Journal Articles

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Alessandro Malara, PhD, Cristian Gruppi, PhD, Margherita Massa, Vittorio Rosti, MD, Giovanni Barosi, Alessandra Balduini, MD

Blood (2019) 134 (Supplement_1): 1688.

https://doi.org/10.1182/blood-2019-130735

Published: 2019

Journal Articles

Homozygosity for -2518 G Allele Variant of MCP-1 Predisposes to Adverse Presentation and Outcome in Primary Myelofibrosis

Elena Masselli, MD, Cecilia Carubbi, PhD, Giulia Pozzi, MS, Antonio Percesepe, MD PhD, Rita Campanelli, Laura Villani, Giuliana Gobbi, PhD, Vittorio Rosti, MD, Margherita Massa, Giovanni Barosi, Marco Vitale, MD

Blood (2019) 134 (Supplement_1): 1689.

https://doi.org/10.1182/blood-2019-122750

Published: 2019

Journal Articles

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Chiara Paoli, PhD, Paola Guglielmelli, MD PhD, Francesco Mannelli, MD, Lara Mannelli, MD, Vittorio Rosti, MD, Maria Chiara Finazzi, MD, Elisa Rumi, MD, Marco Ruggeri, Alessandro Pancrazzi, PhD, Carmela Mannarelli, PhD, Guido Finazzi, MD, Maria Luisa Ferrari, BSc, Laura Lissandrini, BSc, Duccio Fantoni, RN, Giovanni Barosi, Mario Cazzola, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1662.

https://doi.org/10.1182/blood-2019-122837

Published: 2019

Journal Articles

Elevated Plasma sIL-2Rα Levels in Primary Myelofibrosis Play a Distinct Role on Disease Progression in JAK2V617F and Calr Mutants

Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Mara De Amici, Carlotta Abbà, MSc, Gianluca Viarengo, Laura Villani, Margherita Massa, Vittorio Rosti, MD

Blood (2019) 134 (Supplement_1): 1678.

https://doi.org/10.1182/blood-2019-125531

Published: 2019

Journal Articles

Shared and Distinctive Ultrastructural Abnormalities Expressed By Megakaryocytes in Bone Marrow and Spleen from Patients with Primary Myelofibrosis

Maria Zingariello, PhD, Vittorio Rosti, MD, Alessandro M. Vannucchi, MD, Paola Guglielmelli, MD PhD, Claudio Bardelli, PhD, Maria Mazzarini, Rosa Alba Rana, Giovanni Barosi, Anna Rita Rita Migliaccio, PhD

Blood (2019) 134 (Supplement_1): 4209.

https://doi.org/10.1182/blood-2019-123140

Published: 2019

Journal Articles

Increased STAT5/STAT3 Intracellular Signaling in Circulating CD34+ Cells of Patients with PMF Correlates with Disease Severity

Carlotta Abbà, MSc, Rita Campanelli, Paolo Catarsi, Laura Villani, Vittorio Abbonante, PhD, Christian Andrea Di Buduo, PhD, Melania Antonietta Sesta, Vittorio Rosti, MD, Giovanni Barosi, MD, Margherita Massa

Blood (2018) 132 (Supplement 1): 4337.

https://doi.org/10.1182/blood-2018-99-114684

Published: 2018

Journal Articles

EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression

Alessandro Malara, PhD, Cristian Gruppi, PhD, Vittorio Abbonante, PhD, Daniele Cattaneo, MD, Luigi De Marco, MD, Alessandra Iurlo, Umberto Gianelli, MD, Andrés F Muro, PhD, Anil K Chauhan, PhD, Vittorio Rosti, MD, Giovanni Barosi, MD, Alessandra Balduini, MD

Blood (2018) 132 (Supplement 1): 1781.

https://doi.org/10.1182/blood-2018-99-116454

Published: 2018

Journal Articles

Abnormal Regulation of Intracellular Calcium in Human Megakaryocytes Contributes to the Pathophysiology of Calr-Mutant Myeloproliferative Neoplasms

Christian Andrea Di Buduo, PhD, Vittorio Abbonante, PhD, Elisa Rumi, MD, Daniela Pietra, PhD, Francesco Moccia, PhD, Giovanni Barosi, MD, Vittorio Rosti, MD, Mario Cazzola, Alessandra Balduini, MD

Blood (2018) 132 (Supplement 1): 1782.

https://doi.org/10.1182/blood-2018-99-116166

Published: 2018

Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Blood (2018) 132 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2018-99-115129

Published: 2018

Journal Articles

RUNX1 Expression Characterizes the Endothelial Cells from the Spleen and Bone Marrow of Patients with Primary Myelofibrosis

Rita Campanelli, Margherita Massa, Laura Villani, Paolo Catarsi, Carlotta Abbà, MSc, Elisabetta Dejana, Monica Corada, Federica Pisati, Giovanni Barosi, MD, Vittorio Rosti, MD

Blood (2018) 132 (Supplement 1): 5486.

https://doi.org/10.1182/blood-2018-99-114564

Published: 2018

Journal Articles

Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Blood (2017) 130 (Supplement 1): 321.

https://doi.org/10.1182/blood.V130.Suppl_1.321.321

Published: 2017

Journal Articles

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Blood (2017) 130 (Supplement 1): 322.

https://doi.org/10.1182/blood.V130.Suppl_1.322.322

Published: 2017

Journal Articles

Shared and Tissue-Specific Genetic Features of Primary Myelofibrosis, Hepatic Fibrosis, Idiopathic Pulmonary Fibrosis and Kidney Fibrosis

Anders B Dohlman, MS, Rosa S Kim, Hadassa Hirschfield, Lilian Varricchio, Fiorella Ciaffoni, Massimiliano Dall'ora, Yujin Hoshida, Naftali Kaminski, Giovanni Barosi, MD, Vittorio Rosti, MD, Scott Friedman, Ronald Hoffman, MD, Anna Rita Migliaccio, PhD

Blood (2017) 130 (Supplement 1): 4196.

https://doi.org/10.1182/blood.V130.Suppl_1.4196.4196

Published: 2017

Journal Articles

Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Blood (2017) 130 (Supplement 1): 4206.

https://doi.org/10.1182/blood.V130.Suppl_1.4206.4206

Published: 2017

Journal Articles

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

Alessandro M. Vannucchi, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Giada Rotunno, MSc, PhD, Carmela Mannarelli, MSc, PhD, Annalisa Pacilli, PhD, Animesh Pardanani, MBBS PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Curtis A. Hanson, MD, Francesco Mannelli, Rhett P. Ketterling, MD, Naseema Gangat, MBBS, Alessandro Rambaldi, MD Prof, Francesco Passamonti, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 200.

https://doi.org/10.1182/blood.V130.Suppl_1.200.200

Published: 2017

Journal Articles

The Role of the Axis TGF-β1/Mir-382-5p/SOD2 in the Induction of Oxidative Stress in CD34+ Hematopoietic Stem/Progenitor Cells from Primary Myelofibrosis

Chiara Rossi, PharmD, Roberta Zini, BSc, PhD, Samantha Ruberti, BSc, PhD, Sebastiano Rontauroli, BSc, Zelia Prudente, BSc, PhD, Greta Barbieri, BSc, Elisa Bianchi, BSc, PhD, Simona Salati, BSc, PhD, Elena Genovese, BSc, Carmela Mannarelli, MSc, PhD, Paola Guglielmelli, MD PhD, Enrico Tagliafico, MDPhD, Vittorio Rosti, MD, Giovanni Barosi, MD, Alessandro M. Vannucchi, Rossella Manfredini, BSc, PhD

Blood (2017) 130 (Supplement 1): 1655.

https://doi.org/10.1182/blood.V130.Suppl_1.1655.1655

Published: 2017

Journal Articles

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Blood (2017) 130 (Supplement 1): 1657.

https://doi.org/10.1182/blood.V130.Suppl_1.1657.1657

Published: 2017

Journal Articles

A Long-Term Safety and Efficacy Study of Givinostat in Patients with Polycythemia Vera: The First 4 Years of Treatment

Guido Finazzi, MD, Alessandra Iurlo, MD PhD, Bruno Martino, Giuseppe Carli, MD, Attilio Guarini, MD, Richard Noble, MD, Alessandro M. Vannucchi, Nikolas von Bubnoff, MD, Marianna De Muro, MD, Paolo Di Bartolomeo, MD, Mary Frances McMullin, MB,Bch BAO, MD FRCPath, Vincenzo Martinelli, MD, Antonio Pezzutto, MD PhD, Vittorio Rosti, MD, Giorgina Specchia, MD, Paolo Bettica, MD PhD, Sara Manzoni, DHSC, BSc, Silvia DI Tollo, DHSC, BSc, Alessandro Rambaldi, MD Prof

Blood (2017) 130 (Supplement 1): 1648.

https://doi.org/10.1182/blood.V130.Suppl_1.1648.1648

Published: 2017

Journal Articles

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Paola Guglielmelli, MD PhD, Giada Rotunno, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Daniela Pietra, PhD, Daniela Cilloni, MD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 351.

https://doi.org/10.1182/blood.V126.23.351.351

Published: 2015

NARROW

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Homozygosity for -2518 G Allele Variant of MCP-1 Predisposes to Adverse Presentation and Outcome in Primary Myelofibrosis

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Elevated Plasma sIL-2Rα Levels in Primary Myelofibrosis Play a Distinct Role on Disease Progression in JAK2V617F and Calr Mutants

Shared and Distinctive Ultrastructural Abnormalities Expressed By Megakaryocytes in Bone Marrow and Spleen from Patients with Primary Myelofibrosis

Increased STAT5/STAT3 Intracellular Signaling in Circulating CD34+ Cells of Patients with PMF Correlates with Disease Severity

EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression

Abnormal Regulation of Intracellular Calcium in Human Megakaryocytes Contributes to the Pathophysiology of Calr-Mutant Myeloproliferative Neoplasms

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

RUNX1 Expression Characterizes the Endothelial Cells from the Spleen and Bone Marrow of Patients with Primary Myelofibrosis

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Shared and Tissue-Specific Genetic Features of Primary Myelofibrosis, Hepatic Fibrosis, Idiopathic Pulmonary Fibrosis and Kidney Fibrosis

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

The Role of the Axis TGF-β1/Mir-382-5p/SOD2 in the Induction of Oxidative Stress in CD34+ Hematopoietic Stem/Progenitor Cells from Primary Myelofibrosis

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

A Long-Term Safety and Efficacy Study of Givinostat in Patients with Polycythemia Vera: The First 4 Years of Treatment

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only